Stock Comparison

LLY vs RXRX

Eli Lilly and Co vs Recursion Pharmaceuticals Inc

The Verdict

RXRX takes this one.

LLY

Eli Lilly and Co

0.5

out of 10

Distressed

Winner

RXRX

Recursion Pharmaceuticals Inc

6.3

out of 10

Solid Pick

Head-to-Head

$965.0B

Market Cap

$1.8B

52.6

P/E Ratio

-2.3

N/A

Profit Margin

-842.9%

N/A

Return on Equity

-54.3%

N/A

Debt-to-Equity

0.0

Moderate

Overall Risk

Aggressive

0.5

DVR Score

6.3

The Deep Dive

LLY0.5/10

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Full LLY Analysis

RXRX6.3/10

Recursion Pharmaceuticals (RXRX) continues to present a compelling long-term vision leveraging its AI/ML Biofoundry to disrupt drug discovery, backed by a strong cash position ($665.2M). The analyst targets (median $9.0) significantly above the current price ($3.44) indicate underlying institutional belief in its future. However, the Q1 2026 earnings revealed a significant challenge: collaboration...

Full RXRX Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.